Amgen (AMGN)
(Delayed Data from NSDQ)
$297.78 USD
-10.03 (-3.26%)
Updated Feb 6, 2025 04:00 PM ET
After-Market: $299.03 +1.25 (0.42%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$297.78 USD
-10.03 (-3.26%)
Updated Feb 6, 2025 04:00 PM ET
After-Market: $299.03 +1.25 (0.42%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
by Zacks Equity Research
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
by Zacks Equity Research
Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.
Company News for Feb 6, 2025
by Zacks Equity Research
Companies In The News Are:AMGN, PRU, ATO, SPG.
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
by Zacks Equity Research
REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
by Zacks Equity Research
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.57% and 2.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
by Zacks Equity Research
Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Markets React to Softening Trade Tariff Policy
by Mark Vickery
An almost immediate retraction of a 25% tariff on imported goods from Mexico prodded this relief trade.
Dow Logs Best January Since 2019: 5 Best Stocks in the ETF
by Sweta Killa
Dow Jones emerges stronger than the other indices, logging the best January since 2019. Let's look at the five stocks that drove the rally.
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
by Sundeep Ganoria
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
The Zacks Analyst Blog Highlights Amgen, Cencora, Humana and Ardent Health
by Zacks Equity Research
Amgen, Cencora, Humana and Ardent Health are included in this Analyst Blog.
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.
Curious about Amgen (AMGN) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates
by Kaibalya Pravo Dey
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Amgen (AMGN) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Amgen (AMGN) settling at $280.30, representing a -0.94% change from its previous close.